CAMBRIDGE, Mass. and DAEJEON, South Korea, July 17, 2023 /PRNewswire/ -- BIORCHESTRA, a biotherapeutics company focused on the treatment of rare and degenerative diseases within the Central Nervous System (CNS), today announced receipt of the grand prize award in the 2023 Merck Advance Biotech Grant Program.
CAMBRIDGE, Mass. and DAEJEON, South Korea, June 1, 2023 /PRNewswire/ -- BIORCHESTRA, a biotherapeutics company focused on the treatment of rare and degenerative diseases within the Central Nervous System (CNS), today announced that Dr. Branden Ryu, Founder, Chairman, and Chief Executive Officer, has accepted an invitation to present the company's discovery program, brain-specific gene targeted siRNA-BTRiN and non human primate (NHP) study outcomes from its lead program – BMD-001 – at the 2023 Biotechnology Innovation Organization International Convention. The conference, the largest in the industry, is scheduled for June 5 - 8, 2023, in Boston.
BIORCHESTRA Scientific Founder, Chairman, and Chief Executive Officer Joins the Republic of Korea (ROK) Official State Visit to the United States
CAMBRIDGE, Mass. and DAEJEON, South Korea, April 24, 2023 /PRNewswire/ -- BIORCHESTRA, a biotherapeutics company focused on rare and degenerative diseases within the Central Nervous System (CNS), today announced significant progress in its lead drug program – BMD-001. Leveraging a proprietary, IV-formulated brain-targeting RNAi Nanomedicine (BTRiNTM) platform that combines targeted cell delivery capabilities and proprietary RNA chemistries, BMD-001 has achieved significant milestones, including:
CAMBRIDGE, Mass. and DAEJEON, South Korea, April 5, 2023 /PRNewswire/ -- BIORCHESTRA, a biotherapeutics company focused on the treatment of rare and degenerative diseases within the Central Nervous System (CNS) leveraging the Biorchestra Drug Delivery System (BDDSTM), which combines targeted cell delivery capabilities and proprietary RNA chemistries to develop first-in-class therapeutics, today announced the appointment of Mr. David Oxley as Chief Business Officer. Mr. Oxley will lead global corporate strategy, including commercial partnerships and capital markets outside Korea. nnDavid Oxley nDavid Oxley nAdding additional strengths to the company's executive team, Mr. Oxley brings extensive experience in developing corporate strategy, leading cross-borders licensing transactions, and global capital markets strategy to the company. With a unique combination of experience in next-generation genetic and cellular medicine, Mr. Oxley's credentials include designing and prosecuting the construction of a complex cellular medicine business plan for Hong Kong Listing in China and the Asia Pacific, commercializing first-in-category products, and leading global cross-border licensing transactions. In addition, Mr. Oxley brings experience building high-performing global sales and marketing organizations to support the company's strategic plan.
CAMBRIDGE, Mass. and DAEJEON, South Korea, March 27, 2023 /PRNewswire/ -- BIORCHESTRA, a biotherapeutics company focused on the treatment of rare and degenerative diseases within the Central Nervous System (CNS) by leveraging the Biorchestra Drug Delivery System (BDDS™), which combines targeted cell delivery capabilities and proprietary RNA chemistries to develop first-in-class therapeutics, today announced an exclusive research, option, and licensing agreement with a global biopharmaceutical company focused on developing transformative medicines. The companies will collaborate on an initial target with the option to expand the collaboration to include several additional targets.
BOSTON, Nov. 8, 2022 /PRNewswire/ -- Dr. Branden Ryu, CEO and Founder of BIORCHESTRA Ltd. (S. Korea), was a featured speaker at a plenary session of the RNA Leaders Congress USA in Boston, MA, on October 18th, 2022. Dr Ryu focused on the new efficacy data of their leading compound, BMD-001, derived from studies in non-human primates that demonstrated clearance of both amyloid-? and tau pathological proteins.
BIORCHESTRA Co., Ltd (BIORCHESTRA), is scheduled to give a company presentation on June 16, 12:00 at BIO International convention, taking place in...
BOSTON, May 12, 2022 /PRNewswire/ -- BIORCHESTRA is a leading RNA therapeutics company that develops novel RNA-based therapeutics and drug delivery systems for neurodegenerative diseases.
SEOUL, South Korea, Feb. 22, 2022 /PRNewswire/ -- BIORCHESTRA is a leading RNA therapeutics company whose lead programs focus on neurodegenerative diseases using its proprietary RNA-based drug and drug delivery platforms. Today, BIORCHESTRA announced the completion of its 45 million USD (54 billion KRW) Series C Fundraising as of 22nd February 2022.